The Government of Canada is investing $1.9m through the COVID-19 Immunity Task Force (CITF) to fund an extension of CanPath’s COVID-19 Antibody Study over a longer period of time, allowing for additional collection of blood samples and questionnaires. The CanPath COVID-19 Antibody Study is implemented in collaboration with CanPath’s regional cohorts, including Atlantic PATH, CARTaGENE (Quebec), Read more about CanPath to Study the Impact and Immune Response to COVID-19 Infection and Vaccination[…]